Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures

Eitemau Tebyg

• Response to “Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures”
  gan: Lu, Yanhui, et al.
  Cyhoeddwyd: (2015)
• No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects
  gan: Vourvahis, Manoli, et al.
  Cyhoeddwyd: (2018)
• Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
  gan: Giaquinto, Carlo, et al.
  Cyhoeddwyd: (2018)
• The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
  gan: Vourvahis, Manoli, et al.
  Cyhoeddwyd: (2014)
• Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
  gan: Stellbrink, Hans-Jürgen, et al.
  Cyhoeddwyd: (2016)